CSIMarket
 
Celcuity Inc   (CELC)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $15.3500 $0.01 0.065%
Day's High: $15.59 Week Perf: 6.6 %
Day's Low: $ 15.12 30 Day Perf: 4.85 %
Volume (M): 228 52 Wk High: $ 16.21
Volume (M$): $ 3,501 52 Wk Avg: $11.39
Open: $15.42 52 Wk Low: $8.39



 Market Capitalization (Millions $) 337
 Shares Outstanding (Millions) 22
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -49
 Cash Flow (TTM) (Millions $) -35
 Capital Exp. (TTM) (Millions $) 0

Celcuity Inc
Celcuity Inc is a biotechnology company that focuses on developing targeted therapeutics for the treatment of cancer. The company specializes in identifying and analyzing unique cellular signaling signatures found in patients' tumor cells. By understanding these signatures, Celcuity aims to develop personalized therapies that target specific molecular pathways and improve patient outcomes. The company utilizes its proprietary CELsignia platform to analyze tumor cells and identify potential therapeutic targets. Celcuity's ultimate goal is to revolutionize cancer treatment by advancing precision medicine and providing patients with more effective and personalized therapies.


   Company Address: 16305 36th Avenue North; Suite 100 Minneapolis 55446 MN
   Company Phone Number: 392-0767   Stock Exchange / Ticker: NASDAQ CELC
   CELC is expected to report next financial results on March 22, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Investigating the Efficacy of Gedatolisib in Combination with Nubeqa for Metastatic Castration Resistant Prostate Cancer

Published Thu, Feb 22 2024 9:05 PM UTC

Celcuity Inc., a clinical-stage biotechnology company, has initiated a Phase 1b/2 clinical trial (CELC-G-201) to evaluate the effectiveness of gedatolisib in combination with Nubeqa for the treatment of metastatic castration resistant prostate cancer (mCRPC). Gedatolisib, Celcuity's leading therapeutic candidate, is a powerful dual inhibitor that selectively targets all Clas...

Celcuity Inc

Expenses Skyrocket in Q2 2023 as Celcuity Inc Faces Uphill Battle, but Investors Stay Hopeful for Bright Future

During the past five days, Celcuity Inc's stock has experienced a slight increase of 0.81%. While this may appear positive at first glance, it is important to note that the year-to-date performance of the stock is still quite negative, standing at -22.39%. Additionally, the stock is currently trading 32.7% above its 52-week low.
Celcuity Inc, a company in the Medical Laboratories sector, recently reported its earnings for the second quarter of 2023. The company announced an operating loss of $-15.055485 million during this period. While this news may seem discouraging, investors remain optimistic about the future prospects of the company. They anticipate the development of a new business model in the near future, which is expected to drive growth and profitability.

Celcuity Inc

Celcuity Inc's Existing Expenditures Surge in 1Q 2023, Prompting Cautious Investor Approach in Healthcare Sector

Investors may want to exercise caution when considering Celcuity Inc as a potential investment opportunity in the Healthcare sector. The company recorded a cumulative net loss of $-44 million during the 12 months ending in the first quarter of 2023, resulting in a negative return on investment (ROI) of -39.03%. Compared to other companies in the same sector, Celcuity's ROI ranks at 4199, with 568 other companies having a higher ROI.
During the January to March 31 reporting cycle, the company's operating loss was recorded at $-12.547537 million, a significant decline from the first quarter of 2022, when it was recorded at $-7.507605 million. While the market observers are hoping for Celcuity to start reporting revenue, the management is reportedly exploring various business models to ensure the introduction of new product lines.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Š 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com